Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare Biotechnology

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc

Bullboard Posts

Comment by GoldenInvestoron Jan 16, 2020 12:20pm

104 Views

Post# 30560771

RE:RE:RE:But modified from December 2019

Correct. It is the same presentation as last week, modified a bit from December when originally crafted.

& that's a GUD thing. JRG & team are executing well on the plan.

i think if they were constantly issuing new presentations that may show they are having trouble executing on their strategy.

they are not. They are hitting more and more singles, doubles and triples.

BIOTOSCANA could turn into a HR as they execute.

i don't think we need to be handheld with daily updates to the corporate presentation.

every few months is GUD with me.

Bullboard Posts

Anaergia signs $25M biomethane deal in Italy